CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Terns Pharmaceuticals, Inc.

TERN
$6.12B
Mid Cap
NASDAQBiotechnology🇺🇸North America59 employees

Drugs in Pipeline

4

Phase 3 Programs

0

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

TERN News
Drug Pipeline
Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Terns Pharmaceuticals, Inc.'s drug pipeline?

CatalystAlert tracks 4 drug candidates in Terns Pharmaceuticals, Inc.'s (TERN) pipeline across Phase 2. Its lead program is TERN-601 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Terns Pharmaceuticals, Inc.'s next FDA catalyst?

CatalystAlert tracks every upcoming catalyst for Terns Pharmaceuticals, Inc. (TERN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.

How do I track TERN biotech catalysts?

Add TERN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Terns Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply